Inozyme Pharma, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Inozyme Pharma, Inc. | INZY - NASDAQ |
$16.00-$16.00 | $16.00 | $20.85 | 7 million | 7/24/2020 |
| BofA Securities, Cowen, Piper Sandler | ||||||
Co-Manager(s): Wedbush PacGrow | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-07-02 Terms Added 2020-07-20 Amended Terms 2020-07-23 | ||||||
Inozyme Pharma, Inc. Quote & Chart - Click for current quote - INZY
IPO Boutique aggregates information on public companies and private companies, such as "INZY" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Inozyme Pharma, Inc. (adapted from Inozyme Pharma, Inc. prospectus):
They are a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "INZY" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.